A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Hoyle, Margaret [1 ]
Paccagnella, Luisa [2 ]
机构：
[1] Pfizer, Milan, Italy
[2] Pfizer Inc, Groton, CT 06340 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181202
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
    Luscan, Gerald
    Paccagnella, Luisa
    Patel, Krish
    BLOOD, 2023, 142
  • [2] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ghosh, Nilanjan
    Munoz, Javier
    Morgan, David S.
    Dang, Nam H.
    Knapp, Mark
    Delioukina, Maria
    Kingsley, Edwin C.
    Anh Tran
    Ping, Jerry
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Ruan, Jia
    BLOOD, 2016, 128 (22)
  • [3] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
    Morschhauser, Franck
    Salles, Gilles
    Le Gouill, Steven
    Tilly, Herve
    Thieblemont, Catherine
    Bouabdallah, Krimo
    Fabiani, Bettina
    Menard, Cedric
    Tarte, Karin
    Cartron, Guillaume
    Houot, Roch
    BLOOD, 2018, 132 (14) : 1486 - 1494
  • [4] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [5] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
    Larsen, Thomas S.
    Manzke, Oliver
    Leibovitz, Daniel
    Arbushites, Michael
    BLOOD, 2022, 140 : 12077 - 12078
  • [6] Positive CHMP Opinion on Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with relapsed or refractory diffuse large B-cell Lymphoma
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (04) : 263 - 263
  • [7] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [8] Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis
    Moore, Donald C.
    Eagers, Keren A.
    Janes, Amanda
    Pineda-Roman, Mauricio
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 239 - 241
  • [9] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
  • [10] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Nedved, Adrienne
    Maddocks, Kami
    Nowakowski, Grzegorz S.
    ONCOLOGIST, 2023, : 199 - 207
12345